Parallax Volatility Advisers, L.P. Bio N Tech Se Call Options Transaction History

Parallax Volatility Advisers, L.P.

13 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	SELL	$78.36 - $124.66 $1.98 Million - $3.15 Million	-25,300 Reduced 46.34%	29,300 $3.48 Million
Q2 2024 Aug 14, 2024	BUY	$80.36 - $102.87 $2.57 Million - $3.29 Million	32,000 Added 141.59%	54,600 $4.39 Million
Q4 2023 Feb 14, 2024	BUY	$90.91 - $112.75 $636,370 - $789,250	7,000 Added 44.87%	22,600 $2.39 Million
Q3 2023 Nov 14, 2023	SELL	$98.5 - $125.08 $5.56 Million - $7.05 Million	-56,400 Reduced 78.33%	15,600 $1.69 Million
Q2 2023 Aug 14, 2023	BUY	$102.58 - $129.66 $7.39 Million - $9.34 Million	72,000 New	72,000 $7.77 Million
Q4 2022 Feb 14, 2023	BUY	$118.43 - $186.05 $923,754 - $1.45 Million	7,800 Added 25.83%	38,000 $5.71 Million
Q3 2022 Nov 14, 2022	SELL	$127.65 - $183.11 $2.86 Million - $4.1 Million	-22,400 Reduced 42.59%	30,200 $4.07 Million
Q2 2022 Aug 15, 2022	BUY	$123.25 - $186.24 $3.81 Million - $5.75 Million	30,900 Added 142.4%	52,600 $7.84 Million
Q1 2022 May 16, 2022	SELL	$126.25 - $231.85 $5.69 Million - $10.5 Million	-45,100 Reduced 67.51%	21,700 $3.7 Million
Q4 2021 Feb 14, 2022	BUY	$216.64 - $362.52 $2.49 Million - $4.17 Million	11,500 Added 20.8%	66,800 $17.2 Million
Q3 2021 Nov 15, 2021	SELL	$205.93 - $447.23 $12.3 Million - $26.7 Million	-59,700 Reduced 51.91%	55,300 $15.1 Million
Q2 2021 Aug 16, 2021	BUY	$113.32 - $241.49 $10.2 Million - $21.6 Million	89,600 Added 352.76%	115,000 $25.7 Million
Q1 2021 May 14, 2021	BUY	$85.73 - $119.5 $2.18 Million - $3.04 Million	25,400 New	25,400 $2.77 Million

357

38.3M

2.45M

2.29M

Ticker BNTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 242,684,992
Market Cap $27.1B
Description
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II...

Get notified when there are updates to the investment portfolio of Parallax Volatility Advisers, L.P., based on Form 13F filings with the SEC.

Stay updated on Parallax Volatility Advisers, L.P. with notifications on news.